31 Mar 2022
Assets3,069.05
Total Income3,694.52
Profit After Tax-250.87
NET Worth621.98
Reserves and Surplus787.79
Total Borrowing357.95
At a glance
Updated 2026-08-24Akums Drugs and Pharmaceuticals operates in the 441,826.00 segment. The shares listed at ₹725.00, a 6.77% move from the issue price. Akums Drugs and Pharmaceuticals is a Mainboard IPO with an issue size of ₹1,856.74 crore, proposed for listing on BSE, NSE. The offer opens on 30th Jul 2024 and closes on 1st Aug 2024. The issue structure includes a fresh issue of ₹680.99 crore and an offer-for-sale component of ₹1,175.75 crore. The current listing schedule points to 6th Aug 2024.
Issue details
Listing atBSE, NSE
Issue typeBook Build Issue
Issue size₹1,856.74 Cr
Fresh issue₹680.99 Cr
Offer for sale₹1,175.75 Cr
Face value₹2
Price band₹646.00–₹679.00
Allotment2nd Aug 2024
Listing6th Aug 2024
Listing performance
Full performance ↗Issue price₹679.00
Listing price₹725.00
Current price—
Listing gain6.77%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹43.00
GMP / upper price6.33%
Est. listing₹722.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens30th Jul 2024
Closes1st Aug 2024
Allotment2nd Aug 2024
Refund5th Aug 2024
Demat5th Aug 2024
Listing6th Aug 2024
Subscription demand
Full bidding ↗Total63.44×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 22 | ₹14,938 |
Company
Use of proceeds
| Object | Amount |
|---|---|
| Repayment/prepayment of all or certain borrowings of our Company | ₹159.91 Cr |
| Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited | ₹227.09 Cr |
| Funding incremental working capital requirements of our Company | ₹55.00 Cr |
| Pursuing inorganic growth initiatives through acquisitions | ₹27.87 Cr |
| General corporate purposes | ₹167.50 Cr |
Financials
Full financials ↗31 Mar 2023
Assets3,266.53
Total Income3,700.93
Profit After Tax97.82
NET Worth717.19
Reserves and Surplus868.70
Total Borrowing536.97
31 Mar 2024
Assets3,516.37
Total Income4,212.21
Profit After Tax0.79
NET Worth709.50
Reserves and Surplus861.01
Total Borrowing491.56
Trend chart₹ crore
KPIs
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 0.11% |
| ROCE | 3.37% |
| Debt / Equity | 0.69% |
| RoNW | -0.57% |
| PAT Margin | 0.02% |
| EBITDA Margin | 3.73% |
| Price to Book Value | 13.69 |
Issue expenses
| Expense | Amount |
|---|---|
| BRLMs fees and commissions (including underwriting commission) | ₹55.88 Cr |
| Brokerage, selling commission, bidding charges, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs ( | ₹8.32 Cr |
| Other expenses (i) Listing fees, SEBI filing fees, BSE & NSE processing fees, book building software fees, (ii) Other regulatory expenses, (iii) Printing and stationery expenses (iv) Fees payable to the legal counsel (v) Fees payable to other advisors to the Offer (vi) Fees payable to the Registrar to the Offer (vii) Miscellaneous | ₹44.40 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- ICICI Securities Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-08-24.